Ang1
-
Official Full Name
angiogenin, ribonuclease A family, member 1
Species | Cat.# | Product name | Source (Host) | Tag | Protein Length | Price |
---|---|---|---|---|---|---|
Bovine | ANG1-1276B | Recombinant Bovine ANG1 Protein (24-148 aa), His-tagged | E.coli | His | 24-148 aa |
- Ang1 Related Gene Family
Ang1 involved in several pathways and played different roles in them. We selected most pathways Ang1 participated on our site, such as , which may be useful for your reference. Also, other proteins which involved in the same pathway with Ang1 were listed below. Creative BioMart supplied nearly all the proteins listed, you can search them on our site.
Pathway Name | Pathway Related Protein |
---|
Ang1 has several biochemical functions, for example, . Some of the functions are cooperated with other proteins, some of the functions could acted by Ang1 itself. We selected most functions Ang1 had, and list some proteins which have the same functions with Ang1. You can find most of the proteins on our site.
Function | Related Protein |
---|
Ang1 has direct interactions with proteins and molecules. Those interactions were detected by several methods such as yeast two hybrid, co-IP, pull-down and so on. We selected proteins and molecules interacted with Ang1 here. Most of them are supplied by our site. Hope this information will be useful for your research of Ang1.
- Q&As
- Reviews
Q&As (32)
Ask a questionANG1 protein has been implicated in wound healing processes. It can promote angiogenesis, which is crucial for supplying oxygen and nutrients to the healing tissue. Additionally, ANG1 has been shown to enhance endothelial cell migration and the formation of new blood vessels, which can aid in the repair of damaged tissue. Further research is needed to fully understand the mechanisms by which ANG1 contributes to wound healing and to explore its potential therapeutic applications.
Yes, there are ongoing studies investigating the role of ANG1 protein in various cardiovascular diseases, such as ischemic heart disease, peripheral artery disease, and atherosclerosis. Researchers are exploring the therapeutic potential of ANG1 in promoting angiogenesis, improving blood flow, and preventing tissue damage in these conditions.
There are several challenges involved in the development of ANG1 protein therapy. One challenge lies in the delivery of ANG1 to the target tissues, as the protein may have a short half-life or be subject to degradation. Finding efficient and safe delivery methods, such as gene therapy approaches or sustained-release systems, is crucial. Additionally, determining the optimal dosage and treatment schedule, as well as minimizing potential side effects, are also important considerations in the development of ANG1 protein therapy.
Genetic mutations in the ANG1 gene (ANGPT1) have been identified in patients with specific vascular diseases. These mutations can affect ANG1 protein stability, activity, or its interaction with the Tie2 receptor, leading to abnormal angiogenesis and vascular dysfunction. Understanding these mutations can provide insights into the molecular mechanisms underlying these disorders and potentially guide the development of targeted therapies.
ANG1 protein can be delivered using various methods, depending on the therapeutic application. In preclinical and early-stage clinical studies, ANG1 protein has been administered locally, such as through direct injection into target tissues or by incorporating it into biomaterial-based scaffolds for tissue engineering. Other approaches include gene therapy, where the ANG1 gene is delivered using viral vectors, enabling sustained production of the protein within the treated tissues.
The safety and potential side effects of ANG1 protein therapy in humans are still being investigated. It is important to consider the potential for off-target effects and the specific microenvironment of the targeted tissues, as well as potential interactions with other therapies. Further research is required to thoroughly assess the efficacy and safety of ANG1-based therapies.
As of now, there are no ANG1-based therapies that have been approved by regulatory agencies, such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). However, ongoing research and clinical trials may pave the way for potential approval of ANG1-based therapies in the future.
ANG1 protein has shown potential as a therapeutic agent in preclinical studies. Its ability to promote vessel stabilization and reduce vascular leakage has been investigated for the treatment of diseases characterized by abnormal blood vessel formation or dysfunction. However, further research is needed to determine its clinical utility and optimize its therapeutic application.
Genetic mutations in ANG1 itself are relatively rare, but mutations in other genes involved in the ANG1-Tie2 signaling pathway, such as the Tie2 receptor gene (TEK), have been identified and associated with certain vascular diseases. These mutations can disrupt the ANG1-Tie2 interaction and lead to abnormal blood vessel development or function.
Several factors can regulate the expression of ANG1 protein. Hypoxia, which is a condition of low oxygen levels, can upregulate ANG1 expression, as the body responds to inadequate oxygen supply by promoting angiogenic processes. Other factors such as growth factors like vascular endothelial growth factor (VEGF) and inflammatory signals can also modulate the expression of ANG1 in various cell types.
Clinical trials evaluating the therapeutic potential of ANG1 protein or ANG1-based therapies are limited but have been conducted for specific diseases. These trials aim to assess the safety, efficacy, and optimal dosing of ANG1 interventions in various conditions, including cancer, ischemic diseases, and ocular disorders.
Yes, ANG1 protein is a potent regulator of angiogenesis. It promotes vessel maturation and stabilization during angiogenesis through its interaction with the Tie2 receptor.
Yes, ANG1 protein can be used in combination with other therapies. Combining ANG1 with conventional cancer treatments, such as chemotherapy or radiation therapy, may enhance their effectiveness by improving blood vessel normalization and drug delivery to tumors. Additionally, ANG1 protein may also be combined with other angiogenesis inhibitors or growth factors to synergistically enhance its therapeutic effects.
ANG1-Tie2 signaling has been implicated in central nervous system development and maintenance. Disruptions in this signaling pathway have been associated with neurovascular dysfunction and neurodegenerative diseases such as stroke, Alzheimer's disease, and multiple sclerosis. ANG1 and its role in neurovascular interactions are being studied as potential targets for therapeutic interventions.
ANG1 protein has been investigated for its potential application in organ transplantation. The formation of new blood vessels is critical for successful organ engraftment and function after transplantation. ANG1 has been studied for its ability to promote vascularization and improve graft survival, potentially enhancing the outcomes of organ transplantation procedures.
ANG1 protein expression and activity can be regulated at the transcriptional and post-transcriptional levels. Various factors, such as hypoxia, growth factors (e.g., VEGF), and cytokines, can stimulate ANG1 gene expression. Additionally, microRNAs can bind to ANG1 mRNA and regulate its stability and translation, affecting ANG1 protein levels.
ANG1 protein has shown potential as a therapeutic target in cancer therapy. It can promote blood vessel stabilization and normalization, which may help improve drug delivery to solid tumors and enhance the efficacy of chemotherapy and radiation therapy. Additionally, ANG1-Tie2 signaling has been implicated in tumor metastasis, and inhibiting this pathway could potentially prevent cancer cells from spreading to other parts of the body.
While the primary role of ANG1 protein is in vascular biology, emerging evidence suggests possible connections between ANG1 and neurodegenerative diseases. ANG1 has been found to play a role in maintaining the blood-brain barrier integrity, which is important for protecting the brain from harmful substances. Dysfunction of the blood-brain barrier has been implicated in neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease, and ANG1 may contribute to the regulation of this barrier.
Several factors can modulate ANG1 protein activity, including soluble Tie2 receptors, which can bind to and sequester ANG1, thereby inhibiting its binding to endothelial cells. Additionally, certain microRNAs have been found to regulate ANG1 expression levels.
ANG1 protein has shown potential in the treatment of retinal vascular diseases. In conditions such as diabetic retinopathy and age-related macular degeneration, abnormal blood vessel growth and leakage can lead to vision loss. ANG1 has been studied as a potential therapeutic to stabilize and normalize the retinal vasculature, reducing the progression of these diseases and preserving visual function.
Currently, there are no drugs specifically targeting ANG1 protein approved for clinical use. However, research is ongoing to develop novel therapies that can modulate ANG1 activity, such as small molecule agonists or antagonists, to manipulate blood vessel development and improve treatments for various diseases.
Yes, there are natural occurring inhibitors of ANG1 protein. One well-known inhibitor is ANG2 (Angiopoietin 2), which competes with ANG1 for binding to the Tie2 receptor. While ANG1 promotes blood vessel stability, ANG2 can induce vessel destabilization and sprouting. The balance between ANG1 and ANG2 is crucial for proper vessel remodeling and angiogenesis.
ANG1 protein levels can be measured in research or clinical settings using various techniques, such as ELISAs or Western blotting. These methods allow for the quantification of ANG1 protein in biological samples, providing insight into its expression levels and potential role in specific diseases or conditions.
ANG1 has shown potential for therapeutic angiogenesis, particularly in settings where enhanced blood vessel formation and stabilization are desired, such as in ischemic diseases. Studies have explored the use of ANG1 protein or gene therapy to promote angiogenesis and improve tissue reperfusion in preclinical models.
ANG1 protein is produced by various cell types, including endothelial cells, pericytes, smooth muscle cells, and certain tumor cells. It is mainly expressed and secreted by cells in tissues undergoing active angiogenesis or vascular remodeling.
ANG1 binds to the Tie2 receptor, activating downstream signaling pathways involved in angiogenesis and vascular remodeling. This interaction helps to promote endothelial cell survival, enhance vascular integrity, and suppress inflammatory responses during blood vessel development.
While ANG1 primarily regulates blood vessel formation and function, it has also been implicated in lymphangiogenesis, the formation of lymphatic vessels. ANG1-Tie2 signaling has been shown to play a role in the development and maintenance of lymphatic vessels, although the exact mechanisms are still being studied.
Dysregulation of ANG1 protein has been implicated in various pathological conditions such as cancer, diabetic retinopathy, and cardiovascular diseases. Altered ANG1 levels or impaired ANG1-Tie2 signaling can disrupt normal blood vessel formation and maintenance, contributing to disease progression.
Yes, there are ongoing research studies investigating the role of ANG1 protein in various fields. For example, researchers are studying the therapeutic potential of ANG1 in conditions such as diabetic retinopathy, chronic wounds, and cardiovascular diseases. Additionally, ANG1 is being studied in the context of tumor angiogenesis and metastasis, with the aim of developing targeted therapies for cancer treatment.
Yes, ANG1 protein has potential applications in regenerative medicine and tissue engineering. It can promote angiogenesis and blood vessel stabilization, which is critical for the proper delivery of oxygen and nutrients to newly formed tissues. ANG1 has been incorporated into biomaterial-based scaffolds to enhance tissue regeneration and improve the vascularization of engineered tissues.
Yes, there are ongoing clinical trials investigating ANG1 protein therapy in humans. These trials aim to assess the safety and efficacy of ANG1 protein in various disease conditions, including diabetic retinopathy, peripheral artery disease, and chronic venous leg ulcers. Clinical trials are an important step in determining the potential benefits and risks of ANG1 protein therapy in treating these diseases.
ANG1 protein has been investigated for its potential in tissue engineering and regenerative medicine. Its ability to promote angiogenesis and vascularization could be beneficial for generating functional blood vessels within engineered tissues, promoting their integration and survival after transplantation.
Customer Reviews (5)
Write a reviewa manufacturer that offers reliable and high-quality ANG1 protein can significantly enhance the research experience.
In addition to the advantages of ANG1 protein, collaborating with a manufacturer that offers exceptional support can greatly benefit researchers.
Their comprehensive knowledge about ANG1 protein and its applications can assist researchers in optimizing protocols and ensuring reliable results.
Such a manufacturer can provide technical expertise and guidance throughout the experimental process, from experimental design to troubleshooting and data analysis.
by utilizing ANG1 protein in trials and collaborating with a supportive manufacturer, researchers can gain access to a versatile tool that can aid in their understanding of angiogenesis and vascular biology.
Ask a Question for All Ang1 Products
Required fields are marked with *
My Review for All Ang1 Products
Required fields are marked with *